Efficacy and Safety of Adjunctive Therapy Using Single High-Dose S-Ketamine Infusion for Fibromyalgia: A Multicenter, Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Study Protocol
Niti Shrestha, Minying Liu, Shaoning Niu, Hao Cheng, Yongxing Sun, Shenghui Mei, Fang Luo · 2026
Read Efficacy and Safety of Adjunctive Therapy Using Single High-Dose S-Ketamine Infusion for Fibromyalgia: A Multicenter, Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Study Protocol by Niti Shrestha, Minying Liu, Shaoning Niu, Hao Cheng, Yongxing Sun, Shenghui Mei, Fang Luo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13189190.txt.
Description
Niti Shrestha and co-authors set out the plan for a trial in 2026 testing a single strong dose of esketamine for fibromyalgia pain. The condition brings long-term widespread pain, and current drugs act slowly and often weakly. Past esketamine studies used low doses in single centers with few patients.
Ninety-two adults will be split evenly between standard drug care alone and the same care plus one infusion of the drug. All patients take two standard pain drugs, with doses tuned to what each can bear. Follow-up runs for twelve weeks, tracking pain in the first week above all, plus mood, sleep, tiredness, and side effects. Blood levels of the drug will be checked at the infusion's end. The protocol was registered before the trial began.
Catalog record
| CREATOR | Niti Shrestha, Minying Liu, Shaoning Niu, Hao Cheng, Yongxing Sun, Shenghui Mei, Fang Luo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |